Today, AIDS Research Alliance of America focuses its research and development program on several core areas, including the clinical trials of anti-HIV drugs that inhibit the virus in novel ways, and new medical strategies – like microbicides and vaccines – that prevent the spread of HIV. ARAA conducts clinical trials aimed at treating the medical disorders that accompany HIV, including HIV-associated lipodystrophy, diarrhea and neuropathy. Developing strategies that will eliminate HIV viral reservoirs has become a major research initiative of ARAA. This includes its work on prostratin, a potential reservoir ablative agent that ARAA has in-licensed from NIH. In 2008, ARAA filed a new patent on prostratin and its analogues, thus broadening its research platform targeting the HIV reservoirs.
AIDS Research Alliance of America funds its research by using a business model that includes contract research as well as tax-deductible donations from private individuals, corporations and foundations. ARAA conducts clinical trials for major pharmaceutical sponsors including Pfizer, Merck, Theratechnologies, Schering-Plough, Tibotec, NeurogesX, National Institutes of Health, Serono, Bristol-Myers Squibb, Agouron, GlaxoSmith Kline, Orasure Technologies, Gilead Sciences, and many others.
Funders and partners to ARAA have included The Ahmanson Foundation, Capital Group Companies, City of West Hollywood, Concord Music Group, David Michod, Douglas MacBride Kinney, Entertainment AIDS Alliance, The Joseph Drown Foundation, Kaiser Permanente, MacHeist, The MacDonald Family Foundation, The Pepsi Refresh Project, The Silva Watson Moon Walk Fund, The University Wide AIDS Research Program [the University of California], the Division of AIDS [NIH], Until There is a Cure, and many others.